AstraZeneca has paused a £200m expansion of its Cambridge research site, halting its entire £650m UK investment plan.
The Cambridge project had been expected to create 1,000 jobs, following the scrapped £450m vaccine facility in Merseyside.
A company spokesperson said the pause reflects a reassessment of investment needs, with no further comment.
In contrast, AstraZeneca plans $50bn US investment by 2030, funding facilities in Virginia, Maryland, Massachusetts, California, Indiana, and Texas.
The pause follows a week of negative news for UK pharma, including Merck scrapping a £1bn London research centre.
Sir John Bell warned other major pharmaceutical companies may also stop investing in the UK amid uncertainty.
Sanofi called for a clear life sciences plan from the Treasury before resuming significant UK investment.
Eli Lilly also put its £279m London lab project on hold, highlighting industry concerns.
The sector urges NHS pricing reforms, including reducing the clawback rate from nearly 23% to levels seen in Europe.
AstraZeneca Pauses £200m Cambridge Expansion Amid UK Pharma Setbacks
Andrew Rogers
Andrew Rogers is a freelance journalist based in Chicago, USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He graduated with a degree in Journalism from the University of Florida. Over the years, he has contributed to leading outlets such as The New York Times, CNN, and Reuters. Recognized for his sharp reporting and thoughtful analysis, Andrew delivers accurate and timely news that keeps readers updated on key national and global developments.
Add A Comment